Omnimmune Holdings (Omnimmune Holdings) Change In Receivables : $0.00 Mil (TTM As of Sep. 2010)

View and export this data going back to 2007. Start your Free Trial

What is Omnimmune Holdings Change In Receivables?

Omnimmune Holdings's change in receivables for the quarter that ended in Sep. 2010 was $0.00 Mil. It means Omnimmune Holdings's Accounts Receivable stayed the same from Jun. 2010 to Sep. 2010 .

Omnimmune Holdings's change in receivables for the fiscal year that ended in Dec. 2009 was $0.00 Mil. It means Omnimmune Holdings's Accounts Receivable stayed the same from May. 2008 to Dec. 2009 .

Omnimmune Holdings's Accounts Receivable for the quarter that ended in Sep. 2010 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Omnimmune Holdings's liquidation value for the three months ended in Sep. 2010 was $-5.76 Mil.

Omnimmune Holdings Change In Receivables Historical Data

The historical data trend for Omnimmune Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omnimmune Holdings Change In Receivables Chart

Omnimmune Holdings Annual Data

Trend

May07

May08

Dec09

Change In Receivables

Omnimmune Holdings Quarterly Data
	May07	Aug07	Nov07	Feb08	May08	Aug08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10
Change In Receivables	Get a 7-Day Free Trial									-	-	-	-	-

Omnimmune Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2010 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Omnimmune Holdings (GREY:OMMH) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Omnimmune Holdings's Days Sales Outstanding for the quarter that ended in Sep. 2010 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Omnimmune Holdings's accounts receivable are only considered to be worth 75% of book value:

Omnimmune Holdings's liquidation value for the quarter that ended in Sep. 2010 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.005	-	5.763	+	0.75 * 0	+	0.5 * 0
=	-5.76

Omnimmune Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Omnimmune Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Omnimmune Holdings (Omnimmune Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omnimmune Holdings Inc (GREY:OMMH) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

4600 Post Oak Place, Suite 352, Houston, TX, USA, 77027

Website

Omnimmune Holdings Inc is a development-stage biotechnology company, which is engaged in integrating complementary cancer therapeutic, diagnostic and prognostic technologies.

Omnimmune Holdings (Omnimmune Holdings) Headlines

No Headlines